Coronavirus: Vaccination

(asked on 14th December 2020) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he will take to assess the effectiveness of covid-19 vaccines in immunocompromised people post-vaccination.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 23rd December 2020

Prior to the recent authorisation, the efficacy of COVID-19 mRNA Vaccine BNT162b2 was evaluated in two clinical studies. Both studies excluded immunocompromised subjects and therefore no data is available about use of the vaccine when used at the same time as immunosuppressant medicines or the immune response to the vaccine in those on such medications. The second trial allowed inclusion of subjects with autoimmune disorders who were not currently receiving immunosuppressants. There are no specific contraindications or warnings in the product information regarding use in individuals with autoimmune disease.

Evaluation of data for other vaccines is ongoing but will include a robust review of all quality, safety and efficacy data, including in immunocompromised subjects if they were included in clinical trials.

Reticulating Splines